CAPHRI Research Institute, Maastricht University, Maastricht, The Netherlands.
Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands.
Ann Rheum Dis. 2017 Jan;76(1):126-132. doi: 10.1136/annrheumdis-2016-209202. Epub 2016 May 17.
To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for patients with rheumatoid arthritis.
In a discrete choice experiment, European rheumatologists chose between two hypothetical drug treatments for a patient with moderate disease activity. Treatments differed in five attributes: efficacy (improvement and achieved state on disease activity), safety (probability of serious adverse events), patient's preference (level of agreement), medication costs and cost-effectiveness (incremental cost-effectiveness ratio (ICER)). A Bayesian efficient design defined 14 choice sets, and a random parameter logit model was used to estimate relative preferences for rheumatologists across countries. Cluster analyses and latent class models were applied to understand preference patterns across countries and among individual rheumatologists.
Responses of 559 rheumatologists from 12 European countries were included in the analysis (49% females, mean age 48 years). In all countries, efficacy dominated treatment decisions followed by economic considerations and patients' preferences. Across countries, rheumatologists avoided selecting a treatment that patients disliked. Latent class models revealed four respondent profiles: one traded off all attributes except safety, and the remaining three classes disregarded ICER. Among individual rheumatologists, 57% disregarded ICER and these were more likely from Italy, Romania, Portugal or France, whereas 43% disregarded uncommon/rare side effects and were more likely from Belgium, Germany, Hungary, the Netherlands, Norway, Spain, Sweden or UK.
Overall, European rheumatologists are willing to trade between treatment efficacy, patients' treatment preferences and economic considerations. However, the degree of trade-off differs between countries and among individuals.
比较欧洲风湿病学家在为类风湿关节炎患者选择治疗方案时对患者偏好和经济方面的重视程度。
采用离散选择实验,欧洲风湿病学家在两种假设的药物治疗方案中为一位疾病活动度中度的患者进行选择。治疗方案在五个属性上存在差异:疗效(疾病活动度的改善和达到的状态)、安全性(严重不良事件的概率)、患者偏好(认同程度)、药物费用和成本效果(增量成本效果比(ICER))。贝叶斯有效设计定义了 14 个选择集,并使用随机参数对数模型来估计各国风湿病学家的相对偏好。聚类分析和潜在类别模型用于理解各国之间和个别风湿病学家之间的偏好模式。
共纳入来自 12 个欧洲国家的 559 名风湿病学家的回复(49%为女性,平均年龄 48 岁)。在所有国家中,疗效主导着治疗决策,其次是经济考虑和患者偏好。在所有国家中,风湿病学家避免选择患者不喜欢的治疗方案。潜在类别模型揭示了四种应答者特征:一种特征是除安全性外,其他所有属性都可以进行交换,其余三种特征则忽略了 ICER。在个别风湿病学家中,57%的人忽略了 ICER,这些人更可能来自意大利、罗马尼亚、葡萄牙或法国,而 43%的人忽略了不常见/罕见的副作用,更可能来自比利时、德国、匈牙利、荷兰、挪威、西班牙、瑞典或英国。
总体而言,欧洲风湿病学家愿意在治疗效果、患者治疗偏好和经济考虑之间进行权衡。然而,国家之间和个体之间的权衡程度存在差异。